Sign In
Buy FLGT
$18.14
-0.560 (-2.99%)
At Close: Jun 03, 2026
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
07:00am, Friday, 28'th Feb 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
04:05pm, Thursday, 06'th Feb 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine to launch two new hereditary germline tests in the United States through a partnership with Fulgent Genetics.
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
01:25am, Tuesday, 24'th Dec 2024
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside
Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know
10:56am, Monday, 09'th Dec 2024
The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 31.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy
01:00pm, Friday, 22'nd Nov 2024
Fulgent Genetics (FLGT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for November 22nd
07:05am, Friday, 22'nd Nov 2024
SNEX, PKG, APAM, MNDY and FLGT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2024.
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript
02:07am, Monday, 11'th Nov 2024
Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chairman, Chief Executive Offi
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
09:15am, Friday, 08'th Nov 2024
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.39 per share a year ag
Fulgent Reports Third Quarter 2024 Financial Results
07:00am, Friday, 08'th Nov 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent to Participate in Upcoming Conferences
08:00am, Tuesday, 05'th Nov 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a the
Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains?
09:10am, Friday, 01'st Nov 2024
Fulgent Genetics (FLGT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
04:05pm, Thursday, 17'th Oct 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a the
Fulgent Genetics: An NCAV Pick With Profit And Growth Potential
11:32am, Wednesday, 25'th Sep 2024
Fulgent Genetics is transitioning from a diagnostic business to a fully integrated healthcare company, with a focus on oncology. Despite past reliance on COVID-19 test revenues, Fulgent's core busines
